

Curriculum Vitae

■ Personal Details

Name: Faheez Mohamed
E-mail: Faheez.Mohamed@hhft.nhs.uk
GMC Registration: 4328029

■ Education and Qualifications

September 2007 **FRCSEd (Gen Surg)**
Fellow of the Royal College of Surgeons of Edinburgh

March 2005 **MD**
Optimisation of intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy
Doctor of Medicine, Newcastle University

October 2000 **MRCSEd**
Member of the Royal College of Surgeons of Edinburgh

June 1996 **MBChB**
University of Edinburgh Medical School

■ Present Appointment

October 2009 **Consultant Colorectal and General Surgeon with an interest in Peritoneal Surface Malignancy**
Basingstoke and North Hampshire Hospital, United Kingdom

■ Previous Appointments

Jun 09-Oct 09 **Laparoscopic Colorectal Fellow**
Frimley Park Hospital

Aug 08-Jun 09 **Colorectal Research Fellow (Out of Programme Training)**
Basingstoke and North Hampshire Hospital

Oct 03-Aug 08 **Specialist Registrar General Surgery**
Northern Deanery

Aug 03-Oct 03 **Clinical Fellow General Surgery**
Queen Elizabeth Hospital, Gateshead

Jun 01- Jun 03 **Research Fellow in Surgical Oncology**
Washington Cancer Institute USA, Dr Paul Sugarbaker

Aug 97 – Feb 01 **Basic Surgical Training Rotation General Surgery**
Northern Deanery

Aug 96-Aug 97

House Physician/Surgeon
Edinburgh Royal Infirmary

■ Contributions to Academic Meetings

March 2019

Invited Speaker

Mesothelioma Essential Update 2019 Birmingham

National Peritoneal Service

March 2019

Invited speaker /Faculty

ESSO 9th Advanced course on Management of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery

Hamburg, Germany

February 2019

Invited Speaker

Update in Peritoneal Surface Malignancies

Chennai, India

February 2019

Faculty

EuroPMP COST action

Oslo, Norway

November 2018

Invited speaker

Cancer:Advancing into the Future

Shrewsbury

September 2018

Invited speaker

ESCP 14th Scientific and Annual Meeting, Nice, France

Management of Appendix tumours

September 2018

Session chair

11th International Congress on Peritoneal Surface Malignancy

Paris

September 2018

Invited Speaker

Boyes Turner Mesothelioma Study Day, Reading

Cytoreductive Surgery and HIPEC for abdominal mesothelioma

September 2018

Invited speaker

Royal Society of Medicine Surgery Section, Basingstoke

Colorectal Peritoneal metastases

July 2018

Session chair

ACPGBI Annual meeting

Birmingham

June 2018

Invited Speaker

European Society of Anaesthesia, Copenhagen

Fibrinogen supplementation in Cytoreductive surgery for Peritoneal Malignancy

May 2018

Session discussant

ASGBI Annual Scientific meeting

Liverpool

March 2018

Faculty

FRCS Revision Day. Surgical Specialities for the non-specialist

“Colorectal cancer and Diverticular Disease” Basingstoke

February 2018

Invited speaker/Faculty

ESSO 8th Advanced course on the management of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery

Hamburg, Germany

January 2018

IMPACT, Basingstoke

<i>Invited speaker/Faculty</i>	Management of peritoneal disease form colorectal cancer
December 2017	Perioperative Management during CRS and HIPEC in the treatment of Peritoneal Surface Malignancy (PSM)
<i>Invited speaker/Faculty</i>	Berlin
October 2017	4th UK and Ireland Peritoneal Malignancy Conference
<i>Invited Speaker</i>	Dublin
October 2017	ESSO Advanced Course on the Treatment of Peritoneal Surface malignancy
<i>Invited speaker/Faculty</i>	Genk, Belgium
October 2017	Cancer Care Conference: Delivering world class care
<i>Invited speaker</i>	University of Salford
September 2017	International Colorectal Research Summit
<i>Invited Speaker</i>	<i>“Cytoreductive Surgery with HIPEC for the treatment of Colorectal peritoneal metastases”</i> Seoul, Korea
September 2017	Delivering Excellence in Cancer Care
<i>Invited Speaker</i>	London
July 2017	ACPGBI Annual meeting
	Bournemouth
May 2017	ASGBI Annual Scientific meeting
<i>Invited Speaker</i>	<i>“Management of appendix tumours”</i> Glasgow
March 2017	ESSO 7th Advanced course on the management of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery
<i>Invited speaker/Faculty</i>	Hamburg, Germany
March 2017	FRCS Revision Day. Surgical Specialities for the non-specialist
<i>Faculty</i>	<i>“Colorectal cancer and Diverticular Disease”</i> Basingstoke
January 2017	Cambridge Colorectal Away Day
<i>Invited Speaker</i>	<i>“Cytoreductive surgery and HIPEC for colorectal peritoneal metastases”,</i> Addenbrookes Hospital, Cambridge
November 2016	10th International Congress on Peritoneal Surface Malignancies
<i>Faculty</i>	Washington DC, USA
September 2016	KHP Kent & Hampshire Hospitals NET centre 4th meeting
<i>Faculty</i>	London
September 2016	Boyes Turner Mesothelioma Study Day
<i>Invited Speaker</i>	Reading
June 2016	3rd UK Peritoneal Malignancy Conference
<i>Faculty</i>	Birmingham
June 2016	10th Journee Francophone du traitement des carcinoses peritoneales par Chirurgie et Chimotherapie Intra-Peritoneale
<i>Invited speaker</i>	

Nice, France

May 2016 <i>Session chair</i>	International Mesothelioma Interest Group Annual Meeting Birmingham
May 2016 <i>Session chair</i>	ASGBI Belfast Surgical Week
May 2016 <i>Convener</i>	6th Interdisciplinary International Colorectal Masterclass Basingstoke
April 2016 <i>Faculty</i>	Clinical Outcome Registry Workshop Kuwait
April 2016 <i>Invited Speaker</i>	RSM President's Study Day and ACPGBI Wessex meeting Basingstoke
March 2016 <i>Faculty</i>	FRCS Revision Day. Surgical Specialities for the non-specialist Basingstoke
February 2016 <i>Faculty</i>	2nd International Peritoneal Malignancy Workshop for Nurses Allied Health Professionals Basingstoke
October 2015 <i>Faculty</i>	ESSO Course on Peritoneal Surface Malignancy The Christie, Manchester
July 2015 <i>Faculty</i>	Surgical Specialities for the Non-specialist, Basingstoke
June 2015	ACPGBI Digestive Disorders Federation, London
June 2015 <i>Invited speaker</i>	East of England Gynae NCG, Saffron Walden
April 2015 <i>Session Chair</i>	ASGBI Manchester Surgical Week
May 2015 <i>Faculty</i>	Pseudomyxoma Study Day, Basingstoke
February 2015 <i>Facult</i>	First International Peritoneal Malignancy Nurses Conference
February 2015 <i>Invited speaker</i>	British Society of Gastrointestinal Radiology, Leeds
January 2015 <i>Invited Speaker</i>	5th International Colorectal Masterclass, Basingstoke
December 2014 <i>Faculty</i>	Second UK Peritoneal Malignancy Workshop, Basingstoke
November 2014	Colorectal surgery study day for SSP's, Basingstoke

Invited speaker

October 2014

Invited speaker

European Society of Surgical Oncology, Liverpool

September 2014

Invited Speaker

East Anglia Surgical Club, Hinchingsbrooke

June 2014

Invited Speaker

Wessex Intensive Care Society Meeting, Winchester

May 2014

Invited Speaker/Session Chair

ASGBI International Surgical Congress, Harrogate

April 2014

Invited Speaker

The Surgical Specialities for the Non-specialist, Basingstoke

April 2014

Faculty

Colorectal Peritoneal Metastases: Research Challenges, Basingstoke

January 2014

Invited Speaker

**4th International Colorectal Masterclass, Basingstoke
*Cytoreductive Surgery and HIPEC***

November 2013

Invited speaker

**Pseudomyxoma Study Day, Basingstoke
*Cytoreductive Surgery and HIPEC for Pseudomyxoma peritonei***

October 2013

Invited Speaker

**First International Peritoneal Malignancy Workshop,
Basingstoke
*Abdominal mesothelioma***

May 2013

Session Chair

**Pseudomyxoma Peritonei Pathology Consensus Meeting and
Patient's meeting, Basingstoke**

May 2013

Session Chair

ASGBI International Surgical Congress, Glasgow

February 2013

Invited Speaker

**Oncology Grand Rounds, Tom Baker Cancer Centre, Calgary,
Canada
*Management of Peritoneal Metastases in Colorectal Cancer***

October 2012

Invited Speaker

**8th World Congress on Peritoneal Surface Malignancies
*Intraperitoneal Chemotherapy: How should we give it and what
should we give it in?***

October 2012

Invited Speaker

**United Arab Emirates Cancer Congress 2012, Dubai
*Management of colorectal peritoneal metastases***

October 2012

Invited Speaker

**Mesothelioma UK Patients and Carers Day, London
*Peritoneal Mesothelioma***

May 2012

Invited Speaker

**Mesothelioma UK Nurse Action Team Study Day, Basingstoke
*Surgical management of Peritoneal Mesothelioma***

September 2011

British Thoracic Oncology Group/Mesothelioma

Invited Speaker

**Interest Group and Mesothelioma UK Scientific Study Day,
London**

Peritoneal Mesothelioma – The Basingstoke Experience

December 2010

Invited speaker

9th Annual Kuwait Postgraduate Assembly in Surgery

Intraperitoneal Chemotherapy: How does it work?

September 2010

Invited speaker

**7th International Workshop on Peritoneal Surface Malignancy
Uppsala, Sweden**

Carrier Solutions: Does it matter?

November 2008

Session chair

**6th International Workshop on Peritoneal Surface Malignancy
Lyon , France**

Pharmacokinetics of intraperitoneal chemotherapy

■ Awards and Prizes

December 2008

Best Poster Prize

Dukes C colorectal cancer; is the negative lymph node count important?

Colorectal Congress, St Gallen, Switzerland

May 2002

Award for Excellence in Research

Washington Hospital Center Annual Research Day

Washington DC, USA

■ Research

Surgical Oncology Research Fellow at the Washington Cancer Institute, USA, under the supervision of Dr Paul Sugarbaker: June 2001-June 2003.

My research involved clinical and experimental studies in the management of peritoneal surface malignancy focusing on appendiceal malignancy and peritoneal mesothelioma. My main areas of experimental study were optimising intraperitoneal chemotherapy delivery following cytoreductive surgery by comparing different types of chemotherapy carrier solutions in both humans and in an animal model

Funding Sources

Foundation for Applied Research in Gastrointestinal Oncology (FARGO) USA

Salary for 2 year study into optimizing intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy 2001-2003.

2002 Medstar Research Institute, Washington Hospital Centre, Washington D.C, USA

Grant for study entitled “Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia” 2002.

2002 Aventis Clinical Oncology

\$80,000 for study GIA#10186 – Proposal for the study of thermal augmentation of Docetaxel and Melphalan in a mouse model

Co- applicant for the following:

- 2015 Bowel Disease Research Foundation £46,827 for 1 year. Development of an IDEAL framework to standardise the complex intervention of Cytoreductive Surgery for Colorectal Peritoneal Metastases: a necessary step to phase III trials
- 2015 Pelican Cancer Foundation £14,800 for 3 years. Colorectal Peritoneal Metastases Registry. Funding for on line registry involving 5 centres in UK and Ireland to record treatment and outcomes for patients with colorectal peritoneal metastases who undergo Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. 100 patients have been entered into the registry from July 2015
- 2015 Pelican Cancer Foundation £16,800 for 1 year. Thromboelastography (TEG) reduces blood product use in massive surgical blood loss. Investigating use of Fibrinogen to reduce blood loss measured using real-time thromboelastography.
- 2016 Octapharma £500,000 (Principal Investigator) for 1 year Phase II FORMA05 Prospective, Randomised, Controlled Study Investigating the Haemostatic Efficacy and Safety of Fibrinogen Concentrate (Octafibrin) and Cryoprecipitate as Fibrinogen Supplementation Sources in Patients Undergoing Cytoreductive Surgery for Pseudomyxoma Peritonei

■ Membership of Learned Societies

Elected to Scientific Committee of Association of Surgeons of Great Britain and Ireland (2013-2017)
 Re-Elected to Research and Audit Committee of Association of Coloproctology of Great Britain and Ireland (2014-2017) (2017-2020)

■ Positions of Responsibility

Clinical Director General Surgery Hampshire Hospitals Foundation Trust September 2017 to date

Trustee of the Pelican Cancer Foundation

Assigned Educational Supervisor

Accredited appraiser for Hampshire Hospitals Foundation Trust

Royal College of Surgeons of England College Assessor

Clinical Advisor to Pseudomyxoma Survivor patient support group

Editorial Board of Pleura and Peritoneum

Editorial Board of International Journal of Hyperthermia

Vice Chair Management Committee of COST action 17101 EuroPMP

Speciality Adviser to UK National Institute for Health and Care Excellence (NICE)

Examiner for Intercollegiate FRCS examination

■ Publications

Book chapters

Pseudomyxoma Peritonei

Mohamed F, Moran BJ. In : Reed N, Green JA, Gershenson DM, Siddiqui N, Connor R, editors. *Rare and Uncommon Gynecological Cancers*. Springer 2010

Surgery, Hyperthermic Chemoperfusion and Postoperative Chemotherapy: The National Cancer Institute and Washington Hospital Centre Experience.

Carroll NM, Mohamed F, Sugarbaker PH, Alexander HR In: Pass HI, Volgelzang NJ, Carbone M, editors. *Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis and Translational Therapies*. Springer 2005:732

Original papers

Do patients undergoing cytoreductive surgery and HIPEC for peritoneal malignancy need parenteral nutrition?

Swain DR, Yates AL, Mohamed F, Dayal SP, Tzivanakis A, Cecil TD, Moran BJ
Pleura Peritoneum. 2018 Oct 2;3(4):20180123. doi:10.1515/pp-2018-0123.

Biological mesh is a safe and effective method of abdominal wall reconstruction in cytoreductive surgery for peritoneal malignancy.

Tzivanakis A, Dayal SP, Arnold SJ, Mohamed F, Cecil TD, Venkatasubramaniam AK, Moran BJ.
BJS Open. 2018 Aug 2;2(6):464-469. doi: 10.1002/bjs5.93. eCollection 2018 Dec

Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei.

Govaerts K, Chandrakumaran K, Carr NJ, Cecil TD, Dayal S, Mohamed F, Thrower A, Moran BJ.
Eur J Surg Oncol. 2018 Sep;44(9):1371-1377. doi: 10.1016/j.ejso.2018.06.023. Epub 2018 Jul 6

Analysis of Mutation and Loss of Heterozygosity by Whole-Exome Sequencing Yields Insights into Pseudomyxoma Peritonei.

Pengelly RJ, Rowaiye B, Pickard K, Moran B, Dayal S, Tapper W, Mirnezami A, Cecil T, Mohamed F, Carr N, Ennis S. *J Mol Diagn*. 2018 Sep;20(5):635-642. doi: 10.1016/j.jmoldx.2018.05.002. Epub 2018 Jun 22

Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.

Bignell MB, Mehta AM, Alves S, Chandrakumaran K, Dayal SP, Mohamed F, Cecil TD, Moran BJ.
Colorectal Dis. 2018 Aug;20(8):704-710. doi: 10.1111/codi.14057

Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival.

Gilani SNS, Mehta A, Garcia-Fadrique A, Rowaiye B, Jenei V, Dayal S, Chandrakumaran K, Carr N, Mohamed F, Cecil T, Moran B. *Int J Hyperthermia*. 2018 Aug;34(5):578-584. doi: 10.1080/02656736.2018.1434902. Epub 2018 Feb 12

The pre-operative neutrophil-lymphocyte ratio predicts overall and disease-free survival following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with pseudomyxoma peritonei of appendiceal origin.

Rangarajan K, Chandrakumaran K, Dayal S, Mohamed F, Moran BJ, Cecil TD. *Int J Hyperthermia*. 2018 Aug;34(5):559-563. doi: 10.1080/02656736.2017.1384073. Epub 2017 Oct 24

Peritoneal Involvement Is More Common Than Nodal Involvement in Patients With High-Grade Appendix Tumors Who Are Undergoing Prophylactic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Mehta A, Mittal R, Chandrakumaran K, Carr N, Dayal S, Mohamed F, Moran B, Cecil T.
Dis Colon Rectum. 2017 Nov;60(11):1155-1161. doi: 10.1097/DCR.0000000000000869. *PubMed PMID: 28991079*.

Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre.

Chandramohan A, Thrower A, Shah N, Mohamed F.

Br J Radiol. 2017 Aug 22;20170361. doi: 10.1259/bjr.20170361. [Epub ahead of print] PubMed PMID: 28830230.

Risk of Ovarian Involvement in Advanced Colorectal or Appendiceal Tumors Involving the Peritoneum.

Mehta AM, Bignell MB, Alves S, Dayal SP, Mohamed F, Cecil TD, Moran BJ.

Dis Colon Rectum. 2017 Jul;60(7):691-696. doi:10.1097/DCR.0000000000000791. PubMed PMID: 28594718.

Diagnostic and therapeutic laparoscopy in assessment and management of patients with appendiceal neoplasms.

Tan GHC, Shamji T, Mehta A, Chandrakumaran K, Dayal S, Mohamed F, Carr NJ, Rowaiye B, Cecil T, Moran BJ.

Int J Hyperthermia. 2017 Jun 28;1-5. doi: 10.1080/02656736.2017.1338363. [Epub ahead of print] PubMed PMID: 28605985.

Registries on peritoneal surface malignancies throughout the world, their use and their options.

Verwaal VJ, Rau B, Jamali F, Gilly FN, de Hingh I, Takala H, Syk I, Pelz J, Mulsow J, van der Speeten K, Shigeki K, Iversen LH, Mohamed F, Glehen O, Younan R, Yarema R, Gonzalez-Moreno S, O'Dwyer S, Yonemura Y, Sugarbaker P.

Int J Hyperthermia. 2017 Aug;33(5):528-533. doi:10.1080/02656736.2017.1315178. PubMed PMID: 28540833.

The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin. Tan GH, Novo CA, Dayal S, Chandrakumaran K, Mohamed F, Cecil T, Moran BJ. *Eur J Surg Oncol.* 2017 Feb;43(2):388-394. doi: 10.1016/j.ejso.2016.10.009

Colon cancer surgery: is it what you do, or the way you do it that matters? Mohamed F. *The Lancet Gastroenterology & Hepatology.* 2017 Feb 2.

Cytoreductive surgery with intraperitoneal chemotherapy in the management of peritoneal surface malignancy: a pharmacist's perspective. Mistry P, Mohamed F, Dayal S, Cecil TD, Moran BJ. *European Journal of Hospital Pharmacy.* 2016 Jul 1;23(4):233-8.

Pathophysiology and classification of pseudomyxoma peritonei. Bignell M, Carr NJ, Mohamed F. *Pleura and Peritoneum.* 2016 Mar 1;1(1):3-13.

Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Kyriazanos I, Kalles V, Stefanopoulos A, Spiliotis J, Mohamed F. *Surg Oncol.* 2016 Sep;25(3):308-14. doi: 10.1016/j.suronc.2016.06.001. Review.

Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.

Di Fabio F, Mehta A, Chandrakumaran K, Mohamed F, Cecil T, Moran B. *Ann Surg Oncol.* 2016 Jul 5. [Epub ahead of print] PubMed PMID: 27380645.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours.

Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Eur J Surg Oncol. 2016 Jul;42(7):1035-41. doi: 10.1016/j.ejso.2016.03.017. Epub 2016 Apr 9. PubMed PMID: 27132072.

A new internet tool to report peritoneal malignancy extent. PeRitOneal Malignancy Stage Evaluation (PROMISE) application.

Villeneuve L, Thivolet A, Bakrin N, Mohamed F, Isaac S, Valette PJ, Glehen O, Rousset P; BIG-RENAPE and RENAPE Working Groups. Eur J Surg Oncol. 2016 Jun;42(6):877-82. doi:10.1016/j.ejso.2016.03.015. Epub 2016 Mar 28. PubMed PMID: 27067193.

A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Sargant N, Roy A, Simpson S, Chandrakumaran K, Alves S, Coakes J, Knight J, Wilson P, Mohamed F, Cecil T, Moran B. Transfus Med. 2016 Apr;26(2):118-22. doi: 10.1111/tme.12301. Epub 2016 Mar 31. PubMed PMID:27030339.

Procalcitonin levels predict infectious complications and response to treatment in patients undergoing cytoreductive surgery for peritoneal malignancy.

Saeed K, Dale AP, Leung E, Cusack T, Mohamed F, Lockyer G, Arnaudov S, Wade A, Moran B, Lewis G, Dryden M, Cecil T, Cepeda JA Eur J Surg Oncol. 2016 Feb;42(2):234-43. doi: 10.1016/j.ejso.2015.10.004. Epub 2015 Oct 29.

A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process

Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S, Taflampas P, Chapman S, Moran BJ. Am J Surg Pathol. 2016 Jan;40(1):14-26.

The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy.

Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A. Colorectal Dis. 2015 Apr 16. doi: 10.1111/codi.12975. [Epub ahead of print]

Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei one week after complete tumour removal.

Di Fabio F, Aston W, Mohamed F, Chandrakumaran K, Cecil T, Moran B. Colorectal Dis. 2015 Feb 20. doi: 10.1111/codi.12924. [Epub ahead of print]

Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: Comparative study between complete cytoreductive surgery and maximal tumor debulking.

Riss S, Chandrakumaran K, Dayal S, Cecil TD, Mohamed F, Moran BJ Eur J Surg Oncol. 2014 Sep 6. pii: S0748-7983(14)01079-8. doi:10.1016/j.ejso.2014.09.002. [Epub ahead of print] PubMed PMID: 25238953.

Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.

Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Eur J Surg Oncol. 2014 Sep 2. pii:S0748-7983(14)01058-0. doi: 10.1016/j.ejso.2014.08.476. [Epub ahead of print]PubMed PMID: 25216980.

Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients.

Taflampas P, Dayal S, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. *Eur J Surg Oncol.* 2014 Jan 12. pii: S0748-7983(14)00005-5. doi: 10.1016/j.ejso.2013.12.021. [Epub ahead of print] PubMed PMID: 24462284.

Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.

Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil TD, Mohamed F, Moran BJ
Dis Colon Rectum. 2013 Dec;56(12):136672. doi:10.1097/DCR.0b013e3182a62b0d. PubMed PMID: 24201390.

The use of cardiac output monitoring to guide the administration of intravenous fluid during hyperthermic intraperitoneal chemotherapy.

Thanigaimani K, Mohamed F, Cecil T, Moran BJ, Bell J.
Colorectal Dis. 2013 Dec;15(12):1537-42. doi: 10.1111/codi.12444. PubMed PMID: 24119169.

Peritoneal metastases from colorectal cancer: Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Riss S, Mohamed F, Dayal S, Cecil T, Stift A, Bachleitner-Hofmann T, Moran B.
Eur J Surg Oncol. 2013 Sep;39(9):931-7. doi: 10.1016/j.ejso.2013.06.001. Epub 2013 Jun 27

Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study.

Hommell-Fontaine J, Isaac S, Passot G, Decullier E, Traverse-Glehen A, Cotte E, You B, Mohamed F, Gilly FN, Glehen O, Berger F. *Ann Surg Oncol.* 2013 Jun 26. [Epub ahead of print]

Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients.

Bakrin N, Gilly FN, Baratti D, Bereder JM, Quenet F, Lorimier G, Mohamed F, Elias D, Glehen O; Association Française de Chirurgie. *Eur J Surg Oncol.* 2013 Jul;39(7):742-7. doi: 10.1016/j.ejso.2013.02.018. Epub 2013 Mar 16.

Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model.

Passot G, Dupré A, Rivoire M, Mohamed F, Bakrin N, Glehen O
Clin Transl Oncol. 2012 Dec;14(12):931-6

Perioperative management of patients undergoing cytoreductive surgery (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC) for peritoneal surface malignancy – a multi institutional experience.

Bell J, Rylah B, Chambers R, Peet H, Mohamed F, Moran BJ
Ann Surg Oncol. 2012 Dec;19(13):4244-51

Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases.

Carr NJ, Finch J, Ilesley IC, Chandrakumaran K, Mohamed F, Mirnezami A, Cecil T, Moran B
J Clin Pathol 2012 Oct;65(10):919-23

Progression Following Neoadjuvant Systemic Chemotherapy May Not Be a Contraindication to a Curative Approach for Colorectal Carcinomatosis.

Passot G, Vaudoyer D Cotte E, You B, Isaac S, Gilly FN, Mohamed F, Glehen O.
Ann Surg. 2012 Jul;256(1):125-9

Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: Postoperative and long-term results.

Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O, Cotte E.
J Surg Oncol. 2012 106(2):197-203

Laparoscopic total colectomy: Does the indication influence the outcome?

Cotte E, Mohamed F, Nancey S, Francois Y, Glehen O, Flourie B, SaurinJC, Poncet G.
World Journal Gastrointest Surg 2011 Nov 27;3(11) 177- 82

Dukes C colorectal cancer:is the metastatic lymph node ratio important?

Thomas M, Biswas S, Mohamed F, Chandrakumaran K, Jha M, Wilson R
Int J Colorectal Disease 2012 Mar;27(3):309-17

Prognostic and Risk Factors in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma of the Trunk and Extremities

de Lima Vazquez Vinicius, Cristovam Scapulatempo, Natalia Martins Perpetuo, Faheez Mohamed, Teóclito Sachetto de Carvalho, Antônio Talvane Torres de Oliveira, José Getúlio Martins Segalla, and André Lopes Carvalho. *Journal of Skin Cancer.* (2011), Article ID 420796, doi:10.1155/2011/420796

Closed Abdomen Hyperthermic Intraperitoneal Chemotherapy with Irinotecan and Mitomycin C: a Phase I Study.

Cotte E, Passot G, Tod M, Bakrin N, Gilly FN, Steghens A, Mohamed F, Glehen O.
Ann Surg Oncol. 2011 Sep;18(9):2599-603

Operative findings, early complications and long term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin.

Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.
Dis Colon Rectum .2011 Mar;54(3):293-9.

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity.

Bakrin N, Cotte E, Sayag-Beaujard A, Raudrant D, Isaac S, Mohamed F, Gilly F-N, Glehen O.
International Journal of Gynecological Cancer 2010;20(5):809-814

Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.

Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran BJ. *Eur J Surg Oncol Sep* 2010 ;36(12):1156-61

Respect for the laparoscopic port site: lessons in diagnosis, management, and prevention of port-site hernias following laparoscopic colorectal surgery.

Bevan KE, Venkatasubramaniam A, Mohamed F, Moran BJ, Cecil TD. *J Laparoendosc Adv Surg Tech A.* 2010 Jun;20(5):451-4.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience.

Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. *J Clin Oncol* 2009 Dec;27(36):6237-42

Pseudomyxoma Peritonei: Role of 18F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction.

Passot G, Glehen O, Pellet O, Isaac S, Tychyj C, Mohamed F, Giammarile F, Gilly FN, Cotte E. *Eur J Surg Oncol* 2010;36(3):315-23

Morbidity and Mortality with Cytoreductive Surgery and Intraperitoneal Chemotherapy: The importance of a learning curve

Mohamed F, Moran BJ. *The Cancer Journal* May/June 2009; 15(3):196-199

Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients.

Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F, Gilly FN. *World J Surg.* 2007 Sep;31(9):1813-20

Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumour.

Mohamed F, Stuart OA, Glehen O, Urano M, Sugarbaker PH. *Cancer Chemotherapy and Pharmacology* 2006 Dec;58(6):719-24

In vitro thermochemotherapy of colon cancer cell lines with irinotecan alone and combined with mitomycin C.

Le Page S, Kwiatkowski F, Paulin C, Mohamed F, Pezet D, Chipponi J, Benhamed M, Gilly FN, Glehen O. *Hepatogastroenterology* 2006 Sep-Oct;53(71):693-7

Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.

Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, Glehen O. *Annals of Surgical Oncology* 2006 Mar;13(3):405-12

Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study.

Loungnarath R, Causeret S, Bossard N, Mohamed F, Sayag-Beaujard A, Brigand C, Gilly F, Glehen O. *Diseases of the Colon and Rectum* 2005 Jul;48(7):1372-9

Docetaxel and hyperthermia; factors that modify thermal enhancement.

Mohamed F, Stuart OA, Glehen O, Urano M, Sugarbaker PH. *Journal of Surgical Oncology* 2004;88(1):14-20.

Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy.

Glehen O, Mohamed F, Sugarbaker PH. *Annals of Surgery* 2004;240(2):278-285

Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia.

Glehen O, Mohamed F, Gilly FN. *Lancet Oncology* 2004;5(4):219-28

Clinically aggressive pseudomyxoma peritonei; a variant of a histologically indolent process.

Mohamed F, Gething S, Haiba M, Brun EA, Sugarbaker PH. *Journal of Surgical Oncology* 2004;86(1):10-15

Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.

Glehen O, Stuart OA, Mohamed F, Sugarbaker PH. *Cancer Chemotherapy and Pharmacology* 2004;54(1):79-84

Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.

Mohamed F, Marchettini P, Stuart OA, Sugarbaker PH. *Cancer Chemotherapy and Pharmacology* 2003;52(5):405-410

Pharmacokinetics and tissue distribution of intraperitoneal docetaxel with different carrier solutions.

Mohamed F, Stuart OA, Sugarbaker PH. *Journal of Surgical Research* 2003;113(1):114-20

Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.

Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. *Annals of Surgical Oncology* 2003;10(4):463-8

Third look surgery and beyond for appendiceal malignancy with peritoneal surface dissemination.

Mohamed F, Chang D, Sugarbaker PH. *Journal of Surgical Oncology* 2003;83(1):5-12

A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery.

Mohamed F, Marchettini P, Stuart OA, Yoo D, Sugarbaker PH. *European Journal of Surgical Oncology* 2003;29(3):261-265

Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.

Marchettini P, Stuart OA, Mohamed F, Yoo D, Sugarbaker PH. *Cancer Chemotherapy and Pharmacology* 2002;49:499-503

Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.

De Lima Vasquez V, Stuart OA, Mohamed F, Sugarbaker PH. *Cancer Chemotherapy and Pharmacology* 2003;52(2):108-112

Outcome of “kissing stents” for aortoiliac atherosclerotic disease, including the effect on the non-diseased contralateral iliac limb.

Mohamed F, Sarkar B, Timmons G, Mudawi A, Ashour H, Uberoi R. *Cardiovascular and Interventional Radiology* 2002;25:472-5

As part of Peritoneal Surface Oncology Group International (PSOGI)

A Novel Tumour-Node-Metastasis (TNM) Staging System of Diffuse Malignant Peritoneal Mesothelioma Using Outcome Analysis of a Multi-institutional Database

Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH and PSOGI. *Cancer* 2010 [epub ahead of print]

Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma.

Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugarbaker PH; Peritoneal Surface Oncology Group. *Br J Surg.* 2011 Jan;98(1):60-4.

Reviews

A systematic analysis highlighting deficiencies in reported outcomes for patients with stage IV colorectal cancer undergoing palliative resection of the primary tumour.

Harji DP, Vallance A, Selgimann J, Bach S, Mohamed F, Brown J, Fearnhead N. Eur J Surg Oncol. 2018 Jun 23. pii: S0748-7983(18)31134-X. doi: 10.1016/j.ejso.2018.06.012. [Epub ahead of print] Review.

Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

García-Fadrique A, Mehta A, Mohamed F, Dayal S, Cecil T, Moran BJ. J Gastrointest Oncol. 2017 Oct;8(5):915-924. doi: 10.21037/jgo.2017.08.01. Review.PMID: 29184697

Operating personnel safety during the administration of Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Kyriazanos I, Kalles V, Stefanopoulos A, Spiliotis J, Mohamed F. Surg Oncol. 2016 Sep;25(3):308-14. doi:10.1016/j.suronc.2016.06.001. Epub 2016 Jun 23. Review. PubMed PMID: 27566037.

Pathophysiology and Classification of pseudomyxoma peritonei

Bignell M, Carr NJ, Mohamed F. Pleura and Peritoneum 2016;1(1): 3-13

Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases.

Mirnezami R, Moran BJ, Harvey K, Cecil T, Chandrakumaran K, Carr N, Mohamed F, Mirnezami AH. World J Gastroenterol. 2014 Oct14;20(38):14018-32. doi: 10.3748/wjg.v20.i38.14018. PubMed PMID: 25320542.

Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone.

Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, Verwaal VJ, Mohamed F, Mirnezami AH. Br J Cancer. 2014 Oct 14;111(8):1500-8. doi:10.1038/bjc.2014.419. Epub 2014 Sep 16. PubMed PMID: 25225906.

A new standard of care for the management of peritoneal surface malignancy

Mohamed F, Cecil T, Moran B, Sugarbaker P. *Curr Oncol*. 2011 Apr;18(2):e84-96

Pseudomyxoma peritonei

Bevan K, Mohamed F, Moran BJ. *World J Gastrointest Oncol* 2010 January 15;2(1):44-50

The Management of Peritoneal Carcinomatosis from Colorectal Cancer: Current State of Practice

Cotte E, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O. *The Cancer Journal* May/June 2009 ;15(3):243-248

Carrier solutions for intraperitoneal chemotherapy.

Mohamed F, Sugarbaker PH. In: Sugarbaker PH, editor. Peritoneal Surface Malignancy. *Surgical Oncology Clinics of North America* 2003;12(3):813-824

Intraperitoneal taxanes.

Mohamed F, Sugarbaker PH. In: Sugarbaker PH, editor. Peritoneal Surface Malignancy. *Surgical Oncology Clinics of North America* 2003;12(3): 825-833

A review of peritoneal mesothelioma at the Washington Cancer Institute.

Sugarbaker PH, Welch LS, Mohamed F, Glehen O. In: Sugarbaker PH, editor. Peritoneal Surface Malignancy. *Surgical Oncology Clinics of North America* 2003;12(3):605-621,xi.

Peritoneal mesothelioma.

Mohamed F, Sugarbaker PH. *Current Treatment Options in Oncology* 2002; 3(5):375-386

Case Reports

An unusual presentation of intra-abdominal tuberculosis in a young man.

Chaudery M, Mohamed F, Shirol S, Gudgeon M. *J R Soc Med* 2010;103(5):199-201

Peritoneal Cystic Mesothelioma.

Mohamed F, Sethna K, Elias D, Sugarbaker PH. *Journal of Clinical Oncology* 2003;21(7):1419-20

Peritoneal Cystic Mesothelioma- a case series.

Sethna KS, Mohamed F, Marchettini P, Elias D, Sugarbaker PH. *Tumori* 2003;89(1):31-5

Correspondence

Use of factor concentrates for the management of perioperative bleeding: comment.

Sargant N, Roy A, Stanford S, Mohamed F.

J Thromb Haemost. 2018 Aug 2. doi: 10.1111/jth.14256. [Epub ahead of print]

Reply to the Letter From Dr Singhal et al.

Carr NJ, Cecil TD, González-Moreno S, Mohamed F, Moran BJ, Sobin LH, Sugarbaker PH
Am J Surg Pathol. 2016 Sep 14. [Epub ahead of print] PubMed PMID: 27631519.

Benefits of metastasectomy for colorectal cancer. Cecil T, Mohamed F, Moran B.

BMJ. 2014 Jun 18;348:g4033. doi: 10.1136/bmj.g4033. PubMed PMID: 24944123.

Acute appendicitis: leaving normal looking appendices.

Mohamed F, Khoo K. *BMJ* 2006 Sep 23;333(7569):652

Letter to the Editor (re: Peritoneal benign cystic mesothelioma: a case report and review of the literature).

Sethna KS, Mohamed F, Sugarbaker PH. *European Journal of Surgical Oncology* 2002;28(8): 897
